Cargando…
Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?
Understanding the implications of cardiovascular (CV) outcomes data of glucose-lowering agents on the management of type 2 diabetes mellitus can be challenging for many primary practitioners. Amongst different classes of diabetes medications assessed for CV safety, several agents within the sodium-g...
Autores principales: | Deed, Gary, Atherton, John J., d’Emden, Michael, Rasalam, Roy, Sharma, Anita, Sindone, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778570/ https://www.ncbi.nlm.nih.gov/pubmed/31292928 http://dx.doi.org/10.1007/s13300-019-0663-x |
Ejemplares similares
-
Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
por: MacIsaac, Richard J., et al.
Publicado: (2023) -
Sodium‐glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review
por: Rasalam, Roy, et al.
Publicado: (2021) -
Improving Type 2 Diabetes Management in General Practice Using a Second-Generation Basal Insulin Analogue Insulin Glargine 300 U/mL: A Practical Guide
por: Deed, Gary, et al.
Publicado: (2019) -
Comprehensive cardiovascular risk management – what does it mean in practice?
por: Erhardt, Leif, et al.
Publicado: (2007) -
Cardiovascular safety trials of incretin‐based drugs: What do they mean?
por: Yabe, Daisuke, et al.
Publicado: (2016)